Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
BiotechTV - News
00:00
MRT-8102 Targets the NEK7-NLRP3 Inflammasome
Markus Warmuth describes MRT-8102’s NEK7 degradation mechanism and its potential across atherosclerosis, gout, hidradenitis, and broader inflammatory diseases.
Play episode from 05:22
Transcript
